Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Boris Dominik Juelg, Ph.D., M.D.


The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. U01AI145801 (BAROUCH, DAN H.) May 12, 2020 - Apr 30, 2024
    Ad26 Based Therapeutic Vaccines for HIV
    Role: Co-Principal Investigator
  2. R01AI138790 (JUELG, BORIS DOMINIK) Dec 17, 2018 - Nov 30, 2023
    Optimizing HIV-specific T-cell responses by therapeutic vaccination
    Role: Principal Investigator
  3. K08AI106408 (JUELG, BORIS DOMINIK) May 23, 2013 - May 31, 2019
    Vaccine induced T-cell protection against SIV infection
    Role: Principal Investigator

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Atyeo C, Slein MD, Fischinger S, Burke J, Schäfer A, Leist SR, Kuzmina NA, Mire C, Honko A, Johnson R, Storm N, Bernett M, Tong P, Zuo T, Lin J, Zuiani A, Linde C, Suscovich T, Wesemann DR, Griffiths A, Desjarlais JR, Juelg BD, Goudsmit J, Bukreyev A, Baric R, Alter G. Dissecting strategies to tune the therapeutic potential of SARS-CoV-2-specific monoclonal antibody CR3022. JCI Insight. 2021 01 11; 6(1). PMID: 33427208.
    Citations:    Fields:    Translation:HumansAnimalsCells
  2. Pegu A, Borate B, Huang Y, Pauthner MG, Hessell AJ, Julg B, Doria-Rose NA, Schmidt SD, Carpp LN, Cully MD, Chen X, Shaw GM, Barouch DH, Haigwood NL, Corey L, Burton DR, Roederer M, Gilbert PB, Mascola JR, Huang Y. A Meta-analysis of Passive Immunization Studies Shows that Serum-Neutralizing Antibody Titer Associates with Protection against SHIV Challenge. . 2019 Sep 11; 26(3):336-346.e3. PMID: 31513771.
    Citations: 12     Translation:AnimalsCells
  3. Yu WH, Su D, Torabi J, Fennessey CM, Shiakolas A, Lynch R, Chun TW, Doria-Rose N, Alter G, Seaman MS, Keele BF, Lauffenburger DA, Julg B. Predicting the broadly neutralizing antibody susceptibility of the HIV reservoir. JCI Insight. 2019 09 05; 4(17). PMID: 31484826.
    Citations: 3     Fields:    Translation:HumansCells
  4. Julg B, Barouch DH. Neutralizing antibodies for HIV-1 prevention. Curr Opin HIV AIDS. 2019 07; 14(4):318-324. PMID: 31082819.
    Citations: 9     Fields:    Translation:HumansAnimalsCells
  5. Julg B, Dee L, Ananworanich J, Barouch DH, Bar K, Caskey M, Colby DJ, Dawson L, Dong KL, Dubé K, Eron J, Frater J, Gandhi RT, Geleziunas R, Goulder P, Hanna GJ, Jefferys R, Johnston R, Kuritzkes D, Li JZ, Likhitwonnawut U, van Lunzen J, Martinez-Picado J, Miller V, Montaner LJ, Nixon DF, Palm D, Pantaleo G, Peay H, Persaud D, Salzwedel J, Salzwedel K, Schacker T, Sheikh V, Søgaard OS, Spudich S, Stephenson K, Sugarman J, Taylor J, Tebas P, Tiemessen CT, Tressler R, Weiss CD, Zheng L, Robb ML, Michael NL, Mellors JW, Deeks SG, Walker BD. Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meeting. Lancet HIV. 2019 04; 6(4):e259-e268. PMID: 30885693.
    Citations: 41     Fields:    Translation:Humans
  6. Julg B, Alter G. Lymph node fibrosis: a structural barrier to unleashing effective vaccine immunity. J Clin Invest. 2018 07 02; 128(7):2743-2745. PMID: 29781815.
    Citations:    Fields:    Translation:Humans
  7. Julg B, Barouch DH. HIV-1 Latency by Transition. Immunity. 2017 10 17; 47(4):611-612. PMID: 29045893.
    Citations: 1     Fields:    Translation:HumansCells
  8. Julg B, Sok D, Schmidt SD, Abbink P, Newman RM, Broge T, Linde C, Nkolola J, Le K, Su D, Torabi J, Pack M, Pegu A, Allen TM, Mascola JR, Burton DR, Barouch DH. Protective Efficacy of Broadly Neutralizing Antibodies with Incomplete Neutralization Activity against Simian-Human Immunodeficiency Virus in Rhesus Monkeys. J Virol. 2017 10 15; 91(20). PMID: 28768869.
    Citations: 15     Fields:    Translation:HumansAnimalsCells
  9. Julg B, Liu PT, Wagh K, Fischer WM, Abbink P, Mercado NB, Whitney JB, Nkolola JP, McMahan K, Tartaglia LJ, Borducchi EN, Khatiwada S, Kamath M, LeSuer JA, Seaman MS, Schmidt SD, Mascola JR, Burton DR, Korber BT, Barouch DH. Protection against a mixed SHIV challenge by a broadly neutralizing antibody cocktail. Sci Transl Med. 2017 Sep 20; 9(408). PMID: 28931655.
    Citations: 47     Fields:    Translation:AnimalsCells
  10. Julg B, Tartaglia LJ, Keele BF, Wagh K, Pegu A, Sok D, Abbink P, Schmidt SD, Wang K, Chen X, Joyce MG, Georgiev IS, Choe M, Kwong PD, Doria-Rose NA, Le K, Louder MK, Bailer RT, Moore PL, Korber B, Seaman MS, Abdool Karim SS, Morris L, Koup RA, Mascola JR, Burton DR, Barouch DH. Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge. Sci Transl Med. 2017 09 06; 9(406). PMID: 28878010.
    Citations: 40     Fields:    Translation:AnimalsCells
  11. Julg B, Pegu A, Abbink P, Liu J, Brinkman A, Molloy K, Mojta S, Chandrashekar A, Callow K, Wang K, Chen X, Schmidt SD, Huang J, Koup RA, Seaman MS, Keele BF, Mascola JR, Connors M, Barouch DH. Virological Control by the CD4-Binding Site Antibody N6 in Simian-Human Immunodeficiency Virus-Infected Rhesus Monkeys. J Virol. 2017 08 15; 91(16). PMID: 28539448.
    Citations: 19     Fields:    Translation:AnimalsCells
  12. Scheid JF, Horwitz JA, Bar-On Y, Kreider EF, Lu CL, Lorenzi JC, Feldmann A, Braunschweig M, Nogueira L, Oliveira T, Shimeliovich I, Patel R, Burke L, Cohen YZ, Hadrigan S, Settler A, Witmer-Pack M, West AP, Juelg B, Keler T, Hawthorne T, Zingman B, Gulick RM, Pfeifer N, Learn GH, Seaman MS, Bjorkman PJ, Klein F, Schlesinger SJ, Walker BD, Hahn BH, Nussenzweig MC, Caskey M. HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption. Nature. 2016 07 28; 535(7613):556-60. PMID: 27338952.
    Citations: 162     Fields:    Translation:HumansCellsCTClinical Trials
  13. Julg B, Alter G. Broadly Neutralizing Antibodies: Magic Bullets against HIV? Immunity. 2016 06 21; 44(6):1253-4. PMID: 27332729.
    Citations: 1     Fields:    Translation:HumansCells
  14. Vojta A, Dobrinic P, Tadic V, Bockor L, Korac P, Julg B, Klasic M, Zoldoš V. Repurposing the CRISPR-Cas9 system for targeted DNA methylation. Nucleic Acids Res. 2016 07 08; 44(12):5615-28. PMID: 26969735.
    Citations: 182     Fields:    Translation:Cells
  15. Jülg B, Barouch DH. Novel immunological strategies for HIV-1 eradication. J Virus Erad. 2015 Oct 01; 1(4):232-6. PMID: 27482421.
    Citations: 3     
  16. Klatt NR, Bosinger SE, Peck M, Richert-Spuhler LE, Heigele A, Gile JP, Patel N, Taaffe J, Julg B, Camerini D, Torti C, Martin JN, Deeks SG, Sinclair E, Hecht FM, Lederman MM, Paiardini M, Kirchhoff F, Brenchley JM, Hunt PW, Silvestri G. Limited HIV infection of central memory and stem cell memory CD4+ T cells is associated with lack of progression in viremic individuals. PLoS Pathog. 2014 Aug; 10(8):e1004345. PMID: 25167059.
    Citations: 38     Fields:    Translation:HumansCells
  17. Foley MH, Forcier T, McAndrew E, Gonzalez M, Chen H, Juelg B, Walker BD, Irvine DJ. High avidity CD8+ T cells efficiently eliminate motile HIV-infected targets and execute a locally focused program of anti-viral function. PLoS One. 2014; 9(2):e87873. PMID: 24551068.
    Citations: 19     Fields:    Translation:HumansCells
  18. Julg B, Poole D, Ghebremichael M, Castilla C, Altfeld M, Sunpath H, Murphy RA, Walker BD. Factors predicting discordant virological and immunological responses to antiretroviral therapy in HIV-1 clade C infected Zulu/Xhosa in South Africa. PLoS One. 2012; 7(2):e31161. PMID: 22348047.
    Citations: 7     Fields:    Translation:HumansCells
  19. Wright JK, Brumme ZL, Julg B, van der Stok M, Mncube Z, Gao X, Carlson JM, Goulder PJ, Walker BD, Brockman MA, Ndung'u T. Lack of association between HLA class II alleles and in vitro replication capacities of recombinant viruses encoding HIV-1 subtype C Gag-protease from chronically infected individuals. J Virol. 2012 Jan; 86(2):1273-6. PMID: 22090116.
    Citations: 4     Fields:    Translation:HumansCells
  20. Varadarajan N, Julg B, Yamanaka YJ, Chen H, Ogunniyi AO, McAndrew E, Porter LC, Piechocka-Trocha A, Hill BJ, Douek DC, Pereyra F, Walker BD, Love JC. A high-throughput single-cell analysis of human CD8? T cell functions reveals discordance for cytokine secretion and cytolysis. J Clin Invest. 2011 Nov; 121(11):4322-31. PMID: 21965332.
    Citations: 67     Fields:    Translation:HumansCells
  21. Streeck H, Kwon DS, Pyo A, Flanders M, Chevalier MF, Law K, Jülg B, Trocha K, Jolin JS, Anahtar MN, Lian J, Toth I, Brumme Z, Chang JJ, Caron T, Rodig SJ, Milner DA, Piechoka-Trocha A, Kaufmann DE, Walker BD, Altfeld M. Epithelial adhesion molecules can inhibit HIV-1-specific CD8? T-cell functions. Blood. 2011 May 12; 117(19):5112-22. PMID: 21403126.
    Citations: 11     Fields:    Translation:HumansCells
  22. Julg B, Moodley ES, Qi Y, Ramduth D, Reddy S, Mncube Z, Gao X, Goulder PJ, Detels R, Ndung'u T, Walker BD, Carrington M. Possession of HLA class II DRB1*1303 associates with reduced viral loads in chronic HIV-1 clade C and B infection. J Infect Dis. 2011 Mar 15; 203(6):803-9. PMID: 21257739.
    Citations: 24     Fields:    Translation:HumansCells
  23. Chevalier MF, Jülg B, Pyo A, Flanders M, Ranasinghe S, Soghoian DZ, Kwon DS, Rychert J, Lian J, Muller MI, Cutler S, McAndrew E, Jessen H, Pereyra F, Rosenberg ES, Altfeld M, Walker BD, Streeck H. HIV-1-specific interleukin-21+ CD4+ T cell responses contribute to durable viral control through the modulation of HIV-specific CD8+ T cell function. J Virol. 2011 Jan; 85(2):733-41. PMID: 21047960.
    Citations: 94     Fields:    Translation:HumansCells
  24. Quigley M, Pereyra F, Nilsson B, Porichis F, Fonseca C, Eichbaum Q, Julg B, Jesneck JL, Brosnahan K, Imam S, Russell K, Toth I, Piechocka-Trocha A, Dolfi D, Angelosanto J, Crawford A, Shin H, Kwon DS, Zupkosky J, Francisco L, Freeman GJ, Wherry EJ, Kaufmann DE, Walker BD, Ebert B, Haining WN. Transcriptional analysis of HIV-specific CD8+ T cells shows that PD-1 inhibits T cell function by upregulating BATF. Nat Med. 2010 Oct; 16(10):1147-51. PMID: 20890291.
    Citations: 200     Fields:    Translation:HumansAnimalsCells
  25. Julg B, Pereyra F, Buzón MJ, Piechocka-Trocha A, Clark MJ, Baker BM, Lian J, Miura T, Martinez-Picado J, Addo MM, Walker BD. Infrequent recovery of HIV from but robust exogenous infection of activated CD4(+) T cells in HIV elite controllers. Clin Infect Dis. 2010 Jul 15; 51(2):233-8. PMID: 20550452.
    Citations: 60     Fields:    Translation:HumansCells
  26. Julg B, Williams KL, Reddy S, Bishop K, Qi Y, Carrington M, Goulder PJ, Ndung'u T, Walker BD. Enhanced anti-HIV functional activity associated with Gag-specific CD8 T-cell responses. J Virol. 2010 Jun; 84(11):5540-9. PMID: 20335261.
    Citations: 58     Fields:    Translation:HumansCells
  27. Brumme Z, Wang B, Nair K, Brumme C, de Pierres C, Reddy S, Julg B, Moodley E, Thobakgale C, Lu Z, van der Stok M, Bishop K, Mncube Z, Chonco F, Yuki Y, Frahm N, Brander C, Carrington M, Freedberg K, Kiepiela P, Goulder P, Walker B, Ndung'u T, Losina E. Impact of select immunologic and virologic biomarkers on CD4 cell count decrease in patients with chronic HIV-1 subtype C infection: results from Sinikithemba Cohort, Durban, South Africa. Clin Infect Dis. 2009 Sep 15; 49(6):956-64. PMID: 19663693.
    Citations: 13     Fields:    Translation:HumansCells
  28. Julg B, Reddy S, van der Stok M, Kulkarni S, Qi Y, Bass S, Gold B, Nalls MA, Nelson GW, Walker BD, Carrington M, Ndung'u T. Lack of Duffy antigen receptor for chemokines: no influence on HIV disease progression in an African treatment-naive population. . 2009 May 08; 5(5):413-5; author reply 418-9. PMID: 19454341.
    Citations: 15     Translation:HumansCells
  29. Walley NM, Julg B, Dickson SP, Fellay J, Ge D, Walker BD, Carrington M, Cohen MS, de Bakker PI, Goldstein DB, Shianna KV, Haynes BF, Letvin NL, McMichael AJ, Michael NL, Weintrob AC. The Duffy antigen receptor for chemokines null promoter variant does not influence HIV-1 acquisition or disease progression. . 2009 May 08; 5(5):408-10; author reply 418-9. PMID: 19454339.
    Citations: 18     Translation:HumansCells
  30. Julg B, Walker BD. The paradox of incomplete CD4+ cell count restoration despite successful antiretroviral treatment and the need to start highly active antiretroviral therapy early. Clin Infect Dis. 2009 Mar 15; 48(6):795-7. PMID: 19196173.
    Citations:    Fields:    Translation:Humans
  31. Chen H, Piechocka-Trocha A, Miura T, Brockman MA, Julg BD, Baker BM, Rothchild AC, Block BL, Schneidewind A, Koibuchi T, Pereyra F, Allen TM, Walker BD. Differential neutralization of human immunodeficiency virus (HIV) replication in autologous CD4 T cells by HIV-specific cytotoxic T lymphocytes. J Virol. 2009 Apr; 83(7):3138-49. PMID: 19158248.
    Citations: 57     Fields:    Translation:HumansCells
  32. Julg B, Bogner JR. Atriplatrade mark - HIV therapy in one pill. Ther Clin Risk Manag. 2008 Jun; 4(3):573-7. PMID: 18827852.
    Citations: 4     
  33. Jülg B, Elias J, Zahn A, Köppen S, Becker-Gaab C, Bogner JR. Bat-associated histoplasmosis can be transmitted at entrances of bat caves and not only inside the caves. J Travel Med. 2008 Mar-Apr; 15(2):133-6. PMID: 18346250.
    Citations: 5     Fields:    Translation:HumansAnimalsPHPublic Health
  34. Claas GJ, Jülg B, Goebel FD, Bogner J. Metabolic and anthropometric changes one year after switching from didanosine/stavudine to tenofovir in HIV-infected patients. Eur J Med Res. 2007 Feb 26; 12(2):54-60. PMID: 17369118.
    Citations: 6     Fields:    Translation:Humans
  35. Jülg B, Goebel FD. Clinical news from the XVI International AIDS Conference: The attempt of a summing up. Infection. 2006 Oct; 34(5):294-7. PMID: 17033758.
    Citations:    Fields:    Translation:Humans
  36. Jülg B, Bogner JR, Goebel FD. Severe hepatotoxicity associated with the combination of enfuvirtide and tipranavir/ritonavir: case report. AIDS. 2006 Jul 13; 20(11):1563. PMID: 16847416.
    Citations: 1     Fields:    Translation:Humans
  37. Jülg B, Goebel FD. Treatment interruption in HIV therapy: a SMART strategy? Infection. 2006 Jun; 34(3):186-8. PMID: 16804667.
    Citations: 3     Fields:    Translation:Humans
  38. Sauter M, Jülg B, Porubsky S, Cohen C, Fischereder M, Sitter T, Schlondorff D, Gröne HJ. Nephrotic-range proteinuria following pamidronate therapy in a patient with metastatic breast cancer: mitochondrial toxicity as a pathogenetic concept? Am J Kidney Dis. 2006 Jun; 47(6):1075-80. PMID: 16731304.
    Citations: 16     Fields:    Translation:HumansCells
  39. Schmid H, Mühlbayer D, Röling J, Sternfeld T, Jülg B, Schlattner U, Nelson PJ, Bogner JR, Wallimann T, Goebel FD. Macroenzyme creatine kinase (CK) type 2 in HIV-infected patients is significantly associated with TDF and consists of ubiquitous mitochondrial CK. Antivir Ther. 2006; 11(8):1071-80. PMID: 17302377.
    Citations: 1     Fields:    Translation:Humans
  40. Jülg B, Goebel FD. CCR5 antagonists: a new tool in fighting HIV. J HIV Ther. 2005 Dec; 10(4):68-71. PMID: 16519245.
    Citations: 1     Fields:    Translation:HumansCells
  41. Jülg BD, Weidner S, Mayr D. Pulmonary manifestation of a Langerhans cell sarcoma: case report and review of the literature. Virchows Arch. 2006 Mar; 448(3):369-74. PMID: 16328350.
    Citations: 5     Fields:    Translation:HumansCells
  42. Jülg B, Goebel FD. What's new in HIV/AIDS? Neutralizing HIV antibodies: do they really protect? Infection. 2005 Oct; 33(5-6):405-7. PMID: 16258878.
    Citations:    Fields:    Translation:HumansCells
  43. Jülg B, Goebel FD. What's New in HIV/AIDS? Chemokine receptor antagonists: a new era of HIV therapy? Infection. 2005 Oct; 33(5-6):408-10. PMID: 16258879.
    Citations: 2     Fields:    Translation:HumansCells
  44. Jülg BD, Bogner JR, Crispin A, Goebel FD. Progression of renal impairment under therapy with tenofovir. AIDS. 2005 Aug 12; 19(12):1332-3. PMID: 16052093.
    Citations: 7     Fields:    Translation:Humans
  45. Jülg B, Goebel FD. HIV genetic diversity: any implications for drug resistance? Infection. 2005 Aug; 33(4):299-301. PMID: 16091906.
    Citations: 5     Fields:    Translation:HumansCells
  46. Jülg B, Goebel FD. Susceptibility to HIV/AIDS: an individual characteristic we can measure? Infection. 2005 Jun; 33(3):160-2. PMID: 15940420.
    Citations: 4     Fields:    Translation:Humans
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Juelg's Networks
Click the
buttons for more information and interactive visualizations!
Concepts (221)
Co-Authors (30)
Similar People (60)
Same Department 
Physical Neighbors
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.